Roche Touts Benefit Of Health Economic Data For Targeted Cancer Therapies
This article was originally published in The Pink Sheet Daily
Reimbursement for Genentech's Avastin indicates the value of health economic data, Roche Worldwide Pharmaceuticals Head William Burns said
You may also be interested in...
The Centers for Medicare & Medicaid Services’ national coverage determination for oncologics, including Avastin and Erbitux, could be modeled on coverage for PET scans in Alzheimer’s patients, which includes trial registries. CMS expects to complete its coverage determination by Dec. 31.
The number of accounts ordering the oncologic rose from 1,500 to more than 3,000 in the second quarter, with 80% of accounts placing reorders. Genentech says the majority of Avastin's sales come from the front-line setting.
Cost per patient has soared from $500 to $250,000 in past decade, Memorial-Sloan Kettering Research says. It would cost $7.5 bil. to treat all colorectal cancer patients unless some restraints are put in place.